1 / 10

Regulatory Perspective

Regulatory Perspective. John Koerner, Ph.D. Senior Pharmacologist CDER, DCRP. Disclaimer. The views expressed are those of the presenter and do not necessarily reflect those of the FDA. Objectives of SP Studies.

anise
Download Presentation

Regulatory Perspective

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Regulatory Perspective John Koerner, Ph.D. Senior Pharmacologist CDER, DCRP

  2. Disclaimer The views expressed are those of the presenter and do not necessarily reflect those of the FDA

  3. Objectives of SP Studies This (S7A) guideline was developed to help protect clinical trial participants and patients receiving marketed products from potential adverse effects of pharmaceuticals, while avoiding unnecessary use of animals and other resources.

  4. ICH Guidances ICH S7A – Safety Pharmacology “Some safety pharmacology endpoints can be incorporated in the design of toxicology (studies) … “ ICH S6 – Biotechnology Products ICH S9 – Oncology Products

  5. For First in Human Studies Capture relevant CV safety signals to prevent catastrophic, life-threatening AEs HR, BP and ECG

  6. Reduce attrition throughout development Worthwhile goal A regulatory issue when a safety concern to clinical trial participants – say, negative contractility in a fragile patient population.

  7. Stand-Alone CV Safety Pharm Study Conscious, telemeterized animals Typically cross-over design Experience with standard drugs Known (and predictable) sensitivity

  8. CV Endpoints in Toxicology Studies Sensitivity compared to stand-alone study? i.e., what can the study capture, and is this good enough? How best to demonstrate this sensitivity?

  9. Safety Pharmacology Recommendations SPS – Best Practices* HESI Cardiovascular Safety Committee ^ * Best Practice in the conduct of key nonclinical CV assessments…; Leishman, et.al. ^ Cardiovascular Function in nonclinical drug safety assessment…; Sarazan, et.al.

  10. Thank you

More Related